Boston Scientific put volume heavy and directionally bearish
Bearish flow noted in Boston Scientific (BSX) with 6,918 puts trading, or 1.8x expected. Most active are Jul-26 43 puts and Jul-26 42.5 puts, with total volume in those strikes…
Fiscal Year: January - December
Boston Scientific Corporation (BSX), listed on the NYSE, has a market capitalization of $67.12B. As of Jul 07, 2026, the stock is trading at $45.16 per share@else an unavailable price , offering investors a clear view of its current market value. Boston Scientific Corporation is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 18.66, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Boston Scientific Corporation also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
DCF analysis data is not yet available for Boston Scientific Corporation (BSX). The fair value estimate will be displayed once sufficient analyst forecast data is collected.
The proprietary SS Score for Boston Scientific Corporation is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Boston Scientific Corporation, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Boston Scientific Corporation is 19.37, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Boston Scientific Corporation (BSX) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Boston Scientific Corporation (BSX) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Boston Scientific Corporation (BSX) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Boston Scientific Corporation. To access the full SS Score, consider upgrading your subscription.
Boston Scientific Corporation is a significant player in the industry sector, with a market capitalization of $67.12B and a competitive P/E ratio of 18.66. Investors should compare these metrics with industry peers to gauge whether Boston Scientific Corporation is outperforming or underperforming within its sector.
Bearish flow noted in Boston Scientific (BSX) with 6,918 puts trading, or 1.8x expected. Most active are Jul-26 43 puts and Jul-26 42.5 puts, with total volume in those strikes…
Evercore ISI lowered the firm’s price target on Boston Scientific (BSX) to $65 from $78 and keeps an Outperform rating on the shares. The firm’s Q2 preview for MedTech, Life…
Stifel lowered the firm’s price target on Boston Scientific (BSX) to $65 from $75 and keeps a Buy rating on the shares after the firm hosted five deep left atrial…
Jefferies lowered the firm’s price target on Boston Scientific (BSX) to $67 from $100 and keeps a Buy rating on the shares. The firm is lowering its Watchman growth estimates…
Meeting to be held in New York on June 23 hosted by BTIG.
Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Boston Scientific (BSX) to $65 from $90 and keeps an Overweight rating on the shares. The firm notes the…
BofA lowered the firm’s price target on Boston Scientific (BSX) to $61 from $68 and keeps a Buy rating on the shares. Noting that the firm’s services team continues to…
TORONTO, June 08, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTCQX: BSXGF) (the “Company” or “Belo Sun”) today announced a change to its in-country executive leadership team as the Vol...
Truist lowered the firm’s price target on Boston Scientific (BSX) to $64 from $85 and keeps a Buy rating on the shares. The firm notes the recent management commentary regarding…
BTIG analyst Marie Thibault lowered the firm’s price target on Boston Scientific (BSX) to $65 from $80 and keeps a Buy rating on the shares after updating the firm’s forecast…
Bearish flow noted in Boston Scientific (BSX) with 8,246 puts trading, or 2x expected. Most active are Jun-26 47.5 puts and 6/5 weekly 47.5 puts, with total volume in those…
Canaccord lowered the firm’s price target on Boston Scientific (BSX) to $70 from $71 and keeps a Buy rating on the shares. The firm updated its model to reflect slowdowns…
TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTC: BSXGF) (the “Company” or “Belo Sun”) provides the following updates regarding a recent petition filed by the Brazilian...
TD Cowen lowered the firm’s price target on Boston Scientific (BSX) to $61 from $80 and keeps a Buy rating on the shares. The firm updated its model to account…
Wolfe Research downgraded Boston Scientific (BSX) to Peer Perform from Outperform without a price target The firm cut the company’s estimates to reflect the Watchman guidance reduction. It now models…
Boston Scientific shares fell about 12% on Wednesday to their lowest in more than two years, after the medical device maker flagged declining usage of its heart disease device.
TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX:BSX OTCQX:BSXGF) today is pleased to announce that each of the six individuals nominated for election...
TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX, OTCQX: BSXGF) is pleased to provide an update regarding hearings held yesterday before the 6th ...
Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease MARLBOROUGH, Mass. ...
U.S. medical device maker Boston Scientific said on Monday it has invested $1.5 billion in privately held MiRus LLC in return for a 34% equity stake and potential access to the startup's heart-valve...
MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase ...
Agreement includes exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloy MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientif...
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.